Feingold KR, Man MQ, Menon GK et al. (1990) Cholesterol synthesis is required for cutaneous barrier function in mice. Cellular senescence is a physiological process by which cells gradually lose its growth potential to eventually exit cell cycle progression. The concept dates back to 1961, when the 'Hayflick Limit' was discovered in senescent fibroblasts from culture as a result of telomere shortening (Hayflick and Moorhead, 1961 can induce melanocyte senescence in mice and zebrafish (Dankort et al., 2009; Dhomen et al., 2009; Ceol et al., 2011) . Loss of p53 or the phosphatase and tensin homolog, or overexpression of SETDB1, can accelerate melanoma formation, presumably by abrogating oncogene-induced senescence (Patton et al., 2005; Dankort et al., 2009; Ceol et al., 2011 INK4a and Ki-67 are good markers, the others could not distinguish nevi from melanomas. In a subsequent experiment, most nevi (5/7), as well as a subset of metastatic melanomas (3/7), stained positive for SA-b-galactosidase. Thus, the investigators reason that current senescence markers are unable to faithfully differentiate nevi from melanomas, and hence, raise the following question: does the theory of oncogene-induced senescence hold true for human nevi?
These are important observations that warrant investigation by other groups. There have been controversial discussions regarding technical issues on the positive SA-b-galactosidase staining of human nevi (Cotter et al., 2007; GraySchopfer et al., 2008; Michaloglou et al., 2008) . However, this is not the case here, because Tran et al. (2012) successfully show positive SA-bgalactosidase staining in both melanocytes overexpressing B-RAF V600E in vitro and the majority of human nevus samples. It remains a puzzle that some metastatic melanomas also stained positive for SA-b-galactosidase. Perhaps functional assays are required to investigate whether those SA-b-galactosidasepositive cells within metastatic melanoma lesions have lost their proliferative ability. Quintana et al., 2008 Quintana et al., , 2010 demonstrated that melanoma cells isolated from patients' lesions are highly tumorigenic even when as few as five cells are injected into immunodeficient mice, suggesting that most, if not all, melanoma cells have the capacity to indefinitely proliferate. To better interpret the current study, the number of examined metastatic melanoma samples should be increased. Our own unpublished data confirm the presence of senescent cells in human-melanoma-cultured cell lines, and xenograft and patient lesions, as assessed by SA-b-galactosidase, Ki-67, and promyelocytic leukemia protein staining, although the frequency of senescent cells is low in each case.
In addition to a ''gold-standard'' senescence marker such as SA-b-galactosidase, SA heterochromatin foci have been implicated not only as hallmarks of senescent cells, but also as factors in the establishment and reinforcement of oncogene-induced senescence. SA heterochromatin foci can be induced in response to overexpression of an oncogene, such as H-RAS V12 in normal fibroblasts, establishing itself as a bona fide senescence marker. However, SA heterochromatin foci are well retained in proliferating cells that bypass oncogene-induced senescence via depletion of ATM or p53, which may explain that SA heterochromatin foci markers can still be detected in malignant cells harboring the oncogene (Di Micco et al., 2011) . Interestingly, a panel of potential oncogene-induced senescence biomarkers is also unable to differentiate between human and murine pancreatic intraepithelial neoplasia precursors and the more advanced pancreatic ductal adenocarcinoma (Caldwell et al., 2012) . Only SA-b-galactosidase can accurately identify a small and heterogeneous population of non-proliferating premalignant cells in the pancreas (Caldwell et al., 2012) .
Overcoming oncogene-induced senescence for malignant transformation might be a major mechanism for those melanomas derived from benign nevi, but not for those derived from normal melanocytes or dermal stem cell populations. Thus, overcoming senescence is critical for a subgroup of melanomas that is currently not well-defined molecularly. Identifying biomarkers that define senescence-related processes may help us establish novel criteria for those melanomas that evolve from precursor nevus lesions.
